Apollo Hospitals Enterprise Ltd - Company Profile
Powered by 
All the data and insights you need on Apollo Hospitals Enterprise Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Apollo Hospitals Enterprise Ltd Strategy Report
- Understand Apollo Hospitals Enterprise Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Apollo Hospitals Enterprise Catalyst Calendar
Proactively evaluate Apollo Hospitals Enterprise Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Apollo Hospitals Enterprise Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 26 Feb 2021 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 09 Feb 2021 | Phase III Trial Initiation | Indraprastha Apollo Hospitals | - | atezolizumab; durvalumab; nivolumab; pembrolizumab | Oncology | Bladder Cancer; Hepatocellular Carcinoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Solid Tumor | GD Estimates |
| 28 Nov 2020 | Phase II Trial Completion | Apollo Hospitals Enterprise Ltd; Indraprastha Apollo Hospitals | APOLLOHOSP | convalescent plasma | Infectious Disease | Coronavirus Disease 2019 (COVID-19) | Clinical Trial Registry |
| 19 Oct 2020 | Phase IV Trial Initiation | Apollo Hospitals Enterprise Ltd | APOLLOHOSP | methylcobalamin | Hematological Disorders; Nutritional Disorders | Aplastic Anemia; Hypocobalaminemia (Vitamin B12) Deficiency | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer